论文部分内容阅读
头孢噻肟(Cefotaxime,CTX)是第三代头孢菌素,对革蓝氏阳性菌感染的疗效比第一代头孢菌素强,以平行方法比较观察,对金黄色葡萄球菌感染的疗效比头孢噻吩高4～8倍,对链球菌属如肺炎链球菌(化脓性链球菌和缺乳链球菌)的敏感性比头孢噻吩高2～8倍。作者以临床反应和细菌学方法评价CTX对592例革蓝氏阳性菌感染的治疗效果,其中下呼吸道感染251例,皮肤及皮肤组织感染239例,骨及关节感染31例,尿道感染41例和菌血症29例。
Cefotaxime (Cefotaxime, CTX) is the third generation cephalosporin, the infection of gram-positive bacteria than the first-generation cephalosporins stronger than the parallel method to observe the efficacy of Staphylococcus aureus infection than cephalosporins 4 to 8 times higher thiophene, Streptococcus is, such as Streptococcus pneumoniae (Streptococcus pyogenes Streptococcus and Streptococcus) hypersensitivity than cephalothin 2 to 8 times. The authors evaluated clinical effects of CTX on 592 cases of gram-positive infections by clinical and bacteriological methods, including 251 cases of lower respiratory tract infections, 239 cases of skin and skin infections, 31 cases of bone and joint infections, 41 cases of urinary tract infections and Bacteremia in 29 cases.